Fountain Healthcare Partners

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with additional operations in the United States and Australia. The company specializes in developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant underserved population. Mainstay Medical has created an FDA-approved restorative treatment designed to enhance muscle control and improve functionality in the lumbar spine. This therapy aims to help patients regain mobility and enhance their overall quality of life. By collaborating with scientists and clinical experts, Mainstay Medical is committed to advancing solutions for those affected by debilitating back pain.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a significant discovery that identifies CXCR4 as a master regulator of inflammation. This breakthrough positions Ermium Therapeutics to create therapies that control interferons through plasmacytoid dendritic cells, offering potential new treatment options for patients suffering from these conditions. The company has secured a worldwide exclusive license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which supported the project's academic maturation. Ermium Therapeutics has also been recognized for its innovative approach, winning the i-Lab 2019 award from the French Ministry of Research and Higher Education.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in the discovery and development of monoclonal antibodies aimed at treating immune pathologies and addressing significant unmet medical needs. Calypso Biotech focuses on innovative therapies for autoimmune diseases, particularly those affecting patients with severe gastrointestinal conditions such as gastric and pancreatic cancer. The company operates as a semi-virtual organization, leveraging a highly experienced management team with extensive expertise in drug development and a robust scientific network to enhance value for its investors through a portfolio of proprietary antibody candidates.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with additional operations in the United States and Australia. The company specializes in developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant underserved population. Mainstay Medical has created an FDA-approved restorative treatment designed to enhance muscle control and improve functionality in the lumbar spine. This therapy aims to help patients regain mobility and enhance their overall quality of life. By collaborating with scientists and clinical experts, Mainstay Medical is committed to advancing solutions for those affected by debilitating back pain.

Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015 by Brian Shields and David Townley. The company specializes in developing non-surgical treatments for inflammatory sino-nasal diseases, specifically focusing on chronic rhinitis. Neurent Medical offers a single-use, minimally invasive device designed for ENT surgeons, which utilizes a hand-held radio-frequency mechanism. This device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it deploys a microelectrode array to deliver targeted energy. This intervention interrupts the autonomic function of the mucosal structures in the nasal cavities, effectively reversing the inflammatory cascade. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs typically associated with traditional surgical procedures for rhinitis.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Priothera Ltd is a clinical-stage biotechnology company based in Dublin, Ireland, with an additional location in Saint Louis, France. Founded in 2020, Priothera specializes in the development of orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's leading candidate, mocravimod, is designed to reduce the egress of T cell subsets from lymphatic tissue, thereby enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. By providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects, Priothera aims to significantly improve outcomes for patients undergoing such transplants.

Syndesi Therapeutics SA is a biotechnology company based in Louvain-la-Neuve, Belgium, founded in 2018. The company specializes in developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that enables communication between neurons in the brain. This innovative approach aims to address cognitive impairments associated with conditions such as Alzheimer’s Disease. Syndesi Therapeutics holds an exclusive license for its platform technology from UCB, a leader in SV2A research, positioning the company to advance therapeutic options for patients suffering from cognitive disorders.

Inotrem S.A. is a biotechnology company focused on developing innovative immunotherapies for acute and chronic inflammatory conditions. The company specializes in targeting the TREM-1 pathway to modulate unbalanced inflammatory responses. Inotrem's proprietary technology platform has led to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in critical medical situations such as septic shock and myocardial infarction. Additionally, Inotrem is advancing research on new therapeutic modalities aimed at addressing chronic inflammatory diseases. By leveraging its expertise in immunomodulation, Inotrem aims to provide effective treatments for patients suffering from various inflammatory syndromes, enhancing critical care solutions in healthcare.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Velicept Therapeutics, Inc. is a clinical development company based in Malvern, Pennsylvania, established in 2015. The company is dedicated to advancing innovative therapies for conditions such as overactive bladder (OAB) and irritable bowel syndrome (IBS), focusing on unmet medical needs. Its lead program features Solabegron, a novel and selective compound that relaxes bladder smooth muscle by stimulating beta 3-adrenoceptors. This therapeutic approach aims to enhance the quality of life for patients suffering from OAB and IBS. Velicept Therapeutics is committed to developing best-in-class treatment options to transform patient care in these areas.

KaNDy Therapeutics is a biopharmaceutical company specializing in the development of non-hormonal treatments for various symptoms associated with menopause, including hot flashes and nighttime awakenings. Founded in 2017 and based in Stevenage, United Kingdom, the company focuses on providing effective therapies for moderate to severe post-menopausal vasomotor symptoms. Its lead product, NT-814, addresses chronic debilitating conditions related to female sex hormones, offering a viable alternative for patients seeking relief without hormonal interventions. As a subsidiary of Bayer Aktiengesellschaft, KaNDy Therapeutics aims to improve the quality of life for women experiencing hormone-related challenges.

Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015 by Brian Shields and David Townley. The company specializes in developing non-surgical treatments for inflammatory sino-nasal diseases, specifically focusing on chronic rhinitis. Neurent Medical offers a single-use, minimally invasive device designed for ENT surgeons, which utilizes a hand-held radio-frequency mechanism. This device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it deploys a microelectrode array to deliver targeted energy. This intervention interrupts the autonomic function of the mucosal structures in the nasal cavities, effectively reversing the inflammatory cascade. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs typically associated with traditional surgical procedures for rhinitis.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with additional operations in the United States and Australia. The company specializes in developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant underserved population. Mainstay Medical has created an FDA-approved restorative treatment designed to enhance muscle control and improve functionality in the lumbar spine. This therapy aims to help patients regain mobility and enhance their overall quality of life. By collaborating with scientists and clinical experts, Mainstay Medical is committed to advancing solutions for those affected by debilitating back pain.

Syndesi Therapeutics SA is a biotechnology company based in Louvain-la-Neuve, Belgium, founded in 2018. The company specializes in developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that enables communication between neurons in the brain. This innovative approach aims to address cognitive impairments associated with conditions such as Alzheimer’s Disease. Syndesi Therapeutics holds an exclusive license for its platform technology from UCB, a leader in SV2A research, positioning the company to advance therapeutic options for patients suffering from cognitive disorders.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, established in 2016. The company specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting inflammasomes, which are critical in the inflammatory process. Inflazome's innovative therapies are designed to block inflammasome signals, thereby addressing the root causes of inflammation. The company's portfolio includes treatments for a range of conditions, such as neurological disorders like Alzheimer's and Parkinson's, systemic inflammatory diseases, and certain orphan diseases. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG, further enhancing its capacity to deliver targeted therapies in the field of inflammatory diseases.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

Trino Therapeutics is a drug discovery and early development company specializing in anti-inflammatory therapeutics. The company is focused on creating drug candidates from a novel class of compounds known as indane dimers, which are derived from a Taiwanese fern. Its lead candidate aims to be a first-in-class treatment for inflammatory bowel disease (IBD), specifically targeting conditions like ulcerative colitis and Crohn’s disease. In addition to IBD, Trino's proprietary drug class shows potential for broad anti-inflammatory applications, including dermatological, pulmonary, and autoimmune diseases. Through its innovative approach, Trino Therapeutics addresses significant unmet medical needs in the field of inflammatory conditions.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with additional operations in the United States and Australia. The company specializes in developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant underserved population. Mainstay Medical has created an FDA-approved restorative treatment designed to enhance muscle control and improve functionality in the lumbar spine. This therapy aims to help patients regain mobility and enhance their overall quality of life. By collaborating with scientists and clinical experts, Mainstay Medical is committed to advancing solutions for those affected by debilitating back pain.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Genable Technologies Limited is a bio-pharmaceutical company based in Dublin, Ireland, specializing in the development of gene therapies for autosomal dominant genetic diseases. The company focuses on innovative treatments for inherited disorders, notably its RhoNova product aimed at addressing rhodopsin (RHO)-linked autosomal dominant retinitis pigmentosa, a progressive form of inherited blindness caused by mutations in the RHO gene. Genable employs a unique approach that combines suppression and replacement of faulty gene copies using adeno-associated virus (AAV) vectors to deliver RNA interference (RNAi) molecules. This method allows the company to tackle the variability of mutations in dominant diseases without the need to target specific mutations. Genable Technologies was incorporated in 1998 and operates as a subsidiary of Spark Therapeutics, Inc. The company's technology is backed by a comprehensive portfolio of patents in the United States, Europe, and globally.

Amarin Corporation plc, a pharmaceutical company based in Dublin, Ireland, develops and markets therapeutics for cardiovascular disease treatment. Its primary product, Vascepa, is a prescription omega-3 fatty acid capsule used to lower triglyceride levels in adults with severe hypertriglyceridemia. Amarin also has a pipeline for REDUCE-IT, targeting patients with high triglyceride levels on statin therapy. The company sells its products through a direct sales force to wholesalers and specialty pharmacies, and collaborates with Mochida Pharmaceutical Co., Ltd. for further drug development. Amarin's expertise lies in lipid science and the therapeutic benefits of essential fatty acids in cardiovascular disease management.

Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.